Ashvattha Therapeutics to Showcase Topline Phase 2 Data and Recent FDA Alignment at Upcoming Investor and Ophthalmology Meetings
Company to present 40-week topline results from the Phase 2 study of migaldendranib (MGB), a first-in-class subcutaneous nanomedicine, being developed for the treatment of DME and nAMD FDA alignment on Phase 2b/3 trial design provides a clear regulatory path for two well-controlled studies under a single protocol, strengthening the Company’s position with ophthalmology-focused strategics … Read more